CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 578 produtos para "CDK".
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);Cor e Forma:Odour SolidTMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Fórmula:C30H20N6OSPureza:98%Cor e Forma:SolidPeso molecular:512.58CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Fórmula:C24H32F3N5O2Cor e Forma:SolidPeso molecular:479.548CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Fórmula:C17H11ClN2OPureza:98.53%Cor e Forma:SoildPeso molecular:294.735[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Fórmula:C98H138F3N21O39Pureza:98%Cor e Forma:SolidPeso molecular:2291.25PP-C8
PP-C8: PROTAC CDK12-Cyclin K degrader with DC50s 416/412 nM; synergizes with PARP inhibitor against TNBC.Fórmula:C43H51FN12O7Cor e Forma:SolidPeso molecular:866.94CDK12-IN-6
CAS:CDK12-IN-6, a pyrazolotriazine, strongly inhibits CDK12 (IC50 1.19 μM at 2 mM ATP), but not CDK2/Cyclin E or CDK9/Cyclin T1 (both IC50 >20 μM).Fórmula:C20H21F2N9Cor e Forma:SolidPeso molecular:425.448Ribociclib-D8
CAS:Ribociclib-D8 is the deuterated form of Ribociclib (T6199), also known as LEE011, which acts as a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM. Its activity against the cyclin B/CDK1 complex is over 1000 times weaker.Fórmula:C23H30N8OPeso molecular:442.59CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Fórmula:C20H20BrF3N6O2Cor e Forma:SolidPeso molecular:513.319NecroIr2
NecroIr2, an iridium(III) compound, induces necroptosis in Cisplatin-resistant A549R lung cancer cells and disrupts mitochondria.Fórmula:C46H30ClIrN6O2Cor e Forma:SolidPeso molecular:926.44CDK7-IN-2 hydrochloride hydrate
CAS:CDK7-IN-2 HCl hydrate is a potent, specific CDK7 enzyme inhibitor with significant anti-cancer effects.Fórmula:C26H42ClN7O4Cor e Forma:SolidPeso molecular:552.12CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01BSJ-03-204
CAS:BSJ-03-204 is a selective Cdk4/6 degrader.Fórmula:C43H48N10O8Cor e Forma:SolidPeso molecular:832.9CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Fórmula:C18H18BrCl2N5O3Cor e Forma:SolidPeso molecular:503.177JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.161FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Cor e Forma:LiquidKinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Cor e Forma:Odour SolidLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Cor e Forma:Odour SolidLL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77
